ReviewGenes & diseases2025
Fucosylation in digestive inflammatory diseases and cancers: From mechanical studies to clinical translation.
Review in Genes & diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics.Frontiers in immunology · 2026Trial
- FUT2-mediated α1,2-fucosylation in inflammatory bowel disease: mechanisms and translational potential.Molecular biology reports · 2026Review
- Review
- microRNAs bidirectionally regulate FUT1 to modulate α-1,2-fucosylation and cancer-associated biology.The Journal of biological chemistry · 2026Article
- Article
- Emerging Mechanistic Links Between Fucosylation and Senescence in Lung Diseases.Journal of respiratory biology and translational medicine · 2026Article
- Structure, function, and implications of fucosyltransferases in health and disease.Nature communications · 2025Review
- Multi-Omics Alterations in Rat Kidneys upon Chronic Glyphosate Exposure.Biomolecules · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fucosylation is a post-translational modification that attaches fucose to glycoproteins or glycolipids, thereby influencing their biological functions. Consequently, fucosylation proves indispensable for many biological processes, such as ligand-receptor interaction, cell adhesion, and signal transduction, holding critical clinical significance in the genesis and development of diseases. Recent studies further unveiled the clinical significance and molecular mechanism underlying the pathogenetic role of aberrant fucosylation. Herein, we summarize the effects of fucosylation in digestive system inflammatory diseases and cancers, primarily concentrating on the intestine, stomach, liver, and pancreas, from the aspects of the genetic risks of fucosyltransferase mutation, the roles of aberrant fucosylated glycans as diagnostic biomarkers, and the molecular mechanisms of fucosylation-related gene-induced disorders. Finally, we discuss therapeutic strategies targeting fucosylation by fucose or fucosylation inhibitors. We aim to elaborate on the current understanding and provide novel insights into the role of fucosylation in digestive diseases, hoping to facilitate future studies and resolve clinical issues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.